Metabolon Study Suggests Mechanism of Ethylene Glycol Monomethyl Ether-Induced Toxicity

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 13, 2010 - Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, announces the publication of Ethylene Glycol Monomethyl Ether-Induced Toxicity is Mediated through the Inhibition of Flavoprotein Dehydrogenase Enzyme Family”, in the journal Toxicological Sciences on July 8, 2010. The paper was co-authored by Dr. Makoto Takei and colleagues at Daiichi-Sankyo in collaboration with Metabolon scientists.

Ethylene glycol monomethyl ether (EGME) is a widely used industrial solvent that causes hematological, neurological, immunological and reproductive damage as well as other adverse effects in humans and other mammals. Tissues and organs with rapidly dividing cells and high rates of metabolism, such as the testes and thymus, are especially sensitive to EGME. Metabolon's biochemical profiling technology was used to gain a mechanistic understanding of EGME's effects on metabolism. The untargeted metabolomic analysis of serum, urine, liver and testes collected from EGME-treated rats revealed biochemical profiles similar to biochemical signatures observed in humans with multiple acyl-CoA dehydrogenase deficiency (MADD), an inborn error of metabolism. Based on the biochemical analysis the authors propose the mode of action of EGME-induced toxicity is mediated through the inhibition of primary flavoprotein dehydrogenases.

Copies of the paper can be accessed through Toxicological Sciences by clicking here or, alternatively, copy and pasting the link below into your web browser:

http://toxsci.oxfordjournals.org/cgi/reprint/kfq211?ijkey=ouzQ8rGHBcz28KS&keytype=ref

About Metabolon

Metabolon is a diagnostics and services company offering the industry's leading biochemical profiling platform. Metabolon's patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or (919) 595-2200.

 

Contact: Metabolon, Inc.
Matt Zaske, 919-595-2200
mzaske@metabolon.com

 

Posted: July 2010

View comments

Hide
(web1)